



## CURRICULUM VITAE

Wojciech Jan **JURCZAK**

### Personal data:

DOB : 9<sup>th</sup> Aug 1966 in Kraków  
Marital status: married, 2 children  
Medical License No.: 8471647

**Work Address:** Chair of Hematology , Jagiellonian University, Kopernika 17, 31-501 Kraków, Poland  
Department of Haematology, University Hospital, Kopernika 17, 31-501 Kraków, Poland  
Research Medical Center (MCM) Rejtana 2, 30-510 Kraków, Poland

**Home Address:** Kolarczyków 4, 30-225 Kraków, Poland

**Contact:** ph: (+48) 602 33 82 90, e-mail: [wojciech.jurczak@uj.edu.pl](mailto:wojciech.jurczak@uj.edu.pl), [wjurczak.mcm@mp.pl](mailto:wjurczak.mcm@mp.pl)

**Education:**

1984 - 1990	Academy of Medicine - Kraków
1986 - 1988	Jagiellonian University - Faculty of Mathematics and Theoretical Physics
1993 & 1997	Specialization in Internal Medicine (I & II degree)
1996	PhD thesis
2000	Specialization in Hematology
2011	Assoc. Professor (Habilitation)
2017	Professor of Medicine

**Foreign languages:** English, French, German, Russian

**Work Experience:**

since 1991:	<b>Chair of Hematology, Jagiellonian University and Department of Haematology, University Hospital (HO, SHO, registrar, consultant, vice deputy, leader of Lymphoma Team)</b>
since 2007	<b>Research Medical Center (MCM)</b>
1989-90	SHO locums, UCH and Middlesex Sch. of Med. (London)
1996	Registrar, Bone Marrow Transplant Unit, UCH, London
1994-2010	School of Medicine in English, Jagiellonian University

**Memberships:** Polish Lymphoma Research Group (PLRG) - Board Member, Chair of clinical trial Committee, Polish Society of Hematology and Transfusion Medicine (PTHiT), American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), International Cardiooncology Society (ICOS), European Mantle Cell Lymphoma Network (EMCLN)

**Advisory Boards:** Roche, Sandoz Novartis, Celtrion, Celgene, Janssen, Pharmacyclics, Acerta, Gilead, TG Therapeutics, Mundipharma, Spectrum, Novo Nanovector;

### **Professional Interest:**

- Introducing new standards in lymphoma therapy: organizing lymphoma treatment in Małopolska region (about 320 new cases annually) and arranging further medical education for practicing haematologists;
- Charring the PLRG Committee of clinical trials, organizing and coordinating national multicenter trials in Poland, special interest in MCL (mantle cell lymphoma);
- Investigating the role and best timing of autologous and allogeneic transplant procedures in lymphoma patients;

- Performing clinical trials in lymphoma patients, co-author of research papers leading to registration of Ibrutinib, Idelalisib, Belinostat, Tamsitrolimus, Lenalidomide, Brentuximab and Rituximab biosimilar (National coordinator of 17 clinical trial, Principle Investigator of further 55);
- Determining the clinical role of monoclonal antibodies (Rituximab, Alectuzumab, Obinutuzumab, Brentuximab, anti- CD19 MoAbs, anti CD179 MoAbs); developing Rituximab biosimilars, bispecific monoclonal antibodies and radioimmunotherapy (Ibritumomab, Bexatutin);
- Clinical research with drugs interacting with BCR pathway: Bruton kinase inhibitors (Ibrutinib, Acalabrutinib, Merck M7583, Beigene BGB-311) and IP3K inhibitors (Idelalisib, Copansliib, Icyte INCB050465, TGR1202);
- Immunomodulative approach in lymphoma patients: lenalidomide and checkpoint inhibitors;
- Determining the role of anthracycline cardiotoxicity, seeking alternative cytostatics (Pixanthrone);
- Investigating the role for liposomal drugs in oncology (Depocyte, Myocyte).

**Personal Interests:** Marathon running, hiking, mountain climbing



Wojciech Jurczak  
Kraków 28 September 2017

**Abbreviated list of 25 most important publications (according to Scopus: IF > 400, h-index 17, citations > 2000) :**

1. [Research on Biosimilars: pivotal trials and principles.](#) Jurczak W, Vulto AG, Amersdorffer J, Kim WS, Coiffier B. **Lancet Haematol.** 2017 Sep;4(9): e409-e410. doi: 10.1016/S2352-3026(17)30152-7.
2. [Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma \(ASSIST-FL\): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.](#) Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zobel A, Harlin O, Amersdorffer J. **Lancet Haematol.** 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.
3. [Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.](#) Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coiffier B. **Lancet Haematol.** 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.
4. [Comparison of two doses of intravenous tamsitrolimus in patients with relapsed/refractory mantle cell lymphoma.](#) Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J, Lechuga M, Casey M, Boni J, Giza A, Hess G. **Leuk Lymphoma.** 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
5. [Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders.](#) Szmit S, Jurczak W, Zaucha JM, Długosz-Danecka M, Sosnowska-Pasiarska B, Chmielowska E, Joks M, Drozd-Sokołowska J, Knopińska-Posłuszny W, Spychałowicz W, Kumiega B, Charliński G, Morawska M, Słomian G. **Int J Cardiol.** 2017 May 15;235:147-153. doi: 10.1016/j.ijcard.2017.02.073. Epub 2017 Feb 22.
6. [Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.](#) Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. **Lancet Oncol.** 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28.
7. [Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.](#) Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak W, Flinn IW, Kahl BS, Martin P, Kim Y, Shrey S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. **Haematologica.** 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15
8. [Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.](#) Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, Galazka K, Długosz-Danecka M, Machaczka M, Zhang H, Peng R, Morin RD, Rosenquist R, Sander B, Pan-Hammarström Q. **Oncotarget.** 2016 Jun 21;7(25):38180-38190. doi: 10.18632/oncotarget.9500.
9. [Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.](#) Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. **Lancet Oncol.** 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
10. [Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma \(MCL-002; SPRINT\): a phase 2, randomised, multicentre trial.](#) Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva

- J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczkowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo ML, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network. **Lancet Oncol.** 2016 Mar;17(3):319-31. doi: 10.1016/S1470-2045(15)00559-8. Epub 2016 Feb 16.
11. [Postibrutinib outcomes in patients with mantle cell lymphoma.](#) Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, **Jurczak W**, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. **Blood.** 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13.
  12. [Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.](#) Dreyling M, **Jurczak W**, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. **Lancet.** 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Erratum in: *Lancet.* 2016 Feb 20;387(10020):750.
  13. [Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.](#) **Jurczak W**, Ochrem B, Giza A, Zimowska-Curyło D, Górecki T, Boguradzki P, Knopińska-Postuszny W, Stella-Hołowicka B, Walewski J, Joks M, Wróbel T, Zaucha JM. **Pol Arch Med Wewn.** 2015;125(10):741-8. Epub 2015 Sep 3.
  14. [The use of Yttrium-90 Ibritumomab Tiuxetan \(\(90\)Y-IT\) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.](#) **Jurczak W**, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopińska-Postuszny W, Khan O. **Contemp Oncol** 2015;19(1):43-7. doi: 10.5114/wo.2015.50012. Epub 2015 Mar 26.
  15. [Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF \(CLN-19\) Study.](#) O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, **Jurczak W**, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. **J Clin Oncol.** 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22.
  16. [Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.](#) Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, **Jurczak W**, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. **Blood.** 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9.
  17. [PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.](#) Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, **Jurczak W**, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. **N Engl J Med.** 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.
  18. [Premature cardiovascular mortality in lymphoma patients treated with \(R\)-CHOP regimen - a national multicenter study.](#) **Jurczak W**, Szmít S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, Dziętczenia J, Wróbel T, Kumiega B, Zaucha JM, Knopińska-Postuszny W, Spychałowicz W, Prochwicz A, Drohomirecka A, Skotnicki AB. **Int J Cardiol.** 2013 Oct 15;168(6):5212-7. doi: 10.1016/j.ijcard.2013.08.033. Epub 2013 Aug 15.
  19. [Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas.](#) Krawczyk K, **Jurczak W**, Długosz-Danecka M, Zauska-Giza A, Dziętczenia J, Wróbel T, Skotnicki AB. **Pol Arch Med Wewn.** 2013;123(11):589-95. Epub 2013 Sep 24.
  20. [Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.](#) Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, **Jurczak W**, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivoy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. **N Engl J Med.** 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
  21. [Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.](#) Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, **Jurczak W**, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; European Mantle Cell Lymphoma Network. **Ann Oncol.** 2013 Aug;24(8):2119-23. doi: 10.1093/annonc/mdt139. Epub 2013 Apr 24.
  22. [Radioimmunotherapy with \(90\)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.](#) Hohloch K, Zinzani PL, Linkesch W, **Jurczak W**, Deptala A, Lorschbach M, Windemuth-Kiesselbach C, Wulf GG, Truemper LH. **Bone Marrow Transplant.** 2011 Jun;46(6):901-3. doi: 10.1038/bmt.2010.202. Epub 2010 Sep 27. No abstract available.
  23. [Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: analysis of prognostic factors and comparison with a single procedure.](#) Czyz J, Dziadziuszko R, Knopinska-Postuszny W, Hellmann A, Kachel L, Hołowicki J, Czyz A, Komarnicki M, Osowiecki M, Walewski J, **Jurczak W**, Skotnicki A; Polish Lymphoma Research Group. **Leuk Lymphoma.** 2007 Mar;48(3):535-41.
  24. [High prevalence of non-Hodgkin's lymphomas in Polish population--1106 new cases diagnosed according to WHO classification in only one district.](#) **Jurczak W**, Rudzki Z, Gałazka K, Gruchała A, Jaszcz-Gruchała A, Skotnicki AB, Stachura J. **Pol J Pathol.** 2006;57(1):45-52.
  25. [Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.](#) Czyz J, Dziadziuszko R, Knopinska-Postuszny W, Hellmann A, Kachel L, Hołowicki J, Gozdziak J, Hansz J, Avigdor A, Nagler A, Osowiecki M, Walewski J, Mensah P, **Jurczak W**, Skotnicki A, Sedzimirka M, Lange A, Sawicki W, Sulek K, Wach M, Dmoszynska A, Kus A, Robak T, Warzocha K. **Ann Oncol.** 2004 Aug;15(8):1222-30.